Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. - Wikidata - awgldk - TriplyDB

Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.

Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.

http://www.wikidata.org/entity/Q33339438

about

Importance of domain closure for the autoactivation of ERK2.Qingfei Xiaoyan Wan alleviates asthma through multi-target network regulation Characterization of ERK docking domain inhibitors that induce apoptosis by targeting Rsk-1 and caspase-9.Distinct antifibrogenic effects of erlotinib, sunitinib and sorafenib on rat pancreatic stellate cells.Identification of MAP kinase pathways as therapeutic targets in gallbladder carcinoma using targeted parallel sequencing.Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastases BRAFV600E negatively regulates the AKT pathway in melanoma cell lines.Overexpression of eIF3e is correlated with colon tumor development and poor prognosis.Quantitative analysis of ERK2 interactions with substrate proteins: roles for kinase docking domains and activity in determining binding affinity.Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo Mek1/2 gene dosage determines tissue response to oncogenic Ras signaling in the skin.Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032)Small-molecule inhibitors of ERK-mediated immediate early gene expression and proliferation of melanoma cells expressing mutated BRaf High mobility group-box 3 overexpression is associated with poor prognosis of resected gastric adenocarcinoma.Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.Use of inhibitors in the study of MAP kinases.Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy.Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics.Effect of API-1 and FR180204 on cell proliferation and apoptosis in human DLD-1 and LoVo colorectal cancer cells.Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy.A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors.NF‑κB inhibition is associated with OPN/MMP‑9 downregulation in cutaneous melanoma.The discovery of novel experimental therapies for inflammatory arthritis.A multipathway phosphoproteomic signaling network model of idiosyncratic drug- and inflammatory cytokine-induced toxicity in human hepatocytes.Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer.Challenges in the delivery of therapies to melanoma brain metastases.Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate).Cytokine-associated drug toxicity in human hepatocytes is associated with signaling network dysregulation.Cardiac Hormones Target the Ras-MEK 1/2-ERK 1/2 Kinase Cancer Signaling Pathways

P2860

Q30504224-1364B330-78B5-4BB3-8A2B-A0B554F60FC5 Q30544207-75089847-C23D-46FC-B2B4-40A91FD217A2 Q33789572-6B03220B-95B8-4E53-87CF-43FBD2699967 Q33801399-06E66F94-3067-4D3A-827D-8D4ACF64E661 Q33829484-EFFC1B0F-6BB2-471F-B1BA-57C4C5928335 Q33942964-D6E74CCC-1B2C-43AC-B9FF-4DF70989D815 Q34374407-2476638A-7E12-4BD8-8662-16BE3D51C4C9 Q34502089-289A27D9-FA31-42E7-AD08-F61F256E6DB2 Q34509259-CD624347-0843-417E-B9AD-AB3E4032A259 Q34581860-EC08013B-CB6E-4322-B4CE-B764AB696865 Q34887145-021A2AF1-0015-4168-8C7C-2EDF0099032D Q34966603-15E1374F-83BF-462C-93C1-7C998CA93AEA Q35679353-7FA7D016-F1A2-49ED-BB66-694D94EE9AF7 Q36057973-341D3208-5EF5-449C-ACB9-BE7C8A8FA255 Q36276136-4B384D6D-3D30-4B58-A16B-1480131E3F8B Q36529224-2ACC3E77-92E5-4DBB-828E-63C132642F74 Q36642420-63C31DF5-6C96-44A2-93EA-F13D2A14FEB7 Q36862768-BA35FA03-1888-4ADE-882D-6985363D86F8 Q37056518-201769B8-455A-45F9-9A78-D5A95CE201E3 Q37227994-E761BB18-B18B-4F8B-9EAF-885E443BDFD0 Q37236103-42A58E82-9B91-4495-B7E4-7A702F703A18 Q37288375-70E6702B-2EBE-4F2B-ABE5-55676B7CC0B9 Q37460333-86438E71-B89A-4266-9D55-2F53E3B0040C Q37639582-6606F311-5842-4F58-8829-4433B4025579 Q37707767-04E8C52E-AECC-4C02-B4A0-E09149F7758D Q37719255-CA0F7B78-C29D-49BF-A888-9079114AF84A Q37721819-1456A7BC-2C76-4803-B63C-05DD01B7FE29 Q38238743-4FAF4CEE-9E7F-4954-947A-D5C2DCDAD49F Q39331752-8A69D69A-B804-470B-BF60-4F35A4ECF210 Q39514463-36B3D649-CC45-403A-9CEE-6C1EAF3DB44A Q42423679-E50A89D0-C1D2-4F65-B70F-E6B32F1E392E Q42448356-5B51418B-F434-40B9-BA34-604627C2021B

P2860

Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.

http://www.wikidata.org/entity/Q33339438

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.

@ast

Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.

@en

Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.

@nl

type

label

Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.

@ast

Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.

@en

Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.

@nl

prefLabel

Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.

@ast

Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.

@en

Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.

@nl

P1433

Q33339438-8DA5347F-7F8E-466D-9F21-E0B4AD8DC419

P1476

Q33339438-49E2AA12-05B8-4EA1-9930-4E1AD202C2D8

P2093

Q33339438-06CDA498-3720-4FB3-AEF4-8606FD7FE1F0

Q33339438-2708E521-0F38-4730-B37A-B3B9D7B10194

Q33339438-2F0434EE-E63E-4B1D-AF24-3203981170AB

Q33339438-43799381-571A-43A8-BE07-7F7F2656D336

Q33339438-7797D816-7888-4F83-BBD9-DAB91E00F55F

Q33339438-93EAAA8B-E011-460D-B6F8-C1B1A861C6A9

Q33339438-C80EA4F7-7D6A-464D-9378-1246ACABE6F5

Q33339438-E92AD603-D811-4DF0-A6D5-64FF48610AFE

Q33339438-FD5FF100-F8DD-4C01-A4FD-72BE7FF20910

P304

Q33339438-C95A0F64-5C9B-46B7-A744-EA2A342791EB

P31

Q33339438-37093DCA-9C13-4F1A-8DA6-77F0C6873725

P433

Q33339438-093334F1-46CA-4937-B677-A6D044C4B6EA

P478

Q33339438-67921165-EE5E-4626-B95B-DFB8264A00A3

P50

Q33339438-887893D9-F242-4304-9542-364F34DC9648

P577

Q33339438-F710FA55-B060-4BA0-B1E6-0532F556B259

P698

Q33339438-958D8C74-A132-4448-A42F-E056F38C1AFF

P1433

Current Opinion in Investigational Drugs

P1476

Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors

@en

P2093

Agostino Tafuri

http://www.w3.org/2001/XMLSchema#string

Alberto M Martelli

http://www.w3.org/2001/XMLSchema#string

Antonio Bonati

http://www.w3.org/2001/XMLSchema#string

James A McCubrey

http://www.w3.org/2001/XMLSchema#string

John T Lee

http://www.w3.org/2001/XMLSchema#string

Linda S Steelman

http://www.w3.org/2001/XMLSchema#string

Melchiorre Cervello

http://www.w3.org/2001/XMLSchema#string

Michele Milella

http://www.w3.org/2001/XMLSchema#string

Paolo Lunghi

http://www.w3.org/2001/XMLSchema#string

P304

614-630

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Melchiorre Cervello

P577

2008-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18516761

http://www.w3.org/2001/XMLSchema#string